BioSpace News Archive

Neuronascent Inc., is a clinical-stage pharmaceutical company discovering and developing novel regenerative therapies for age-related brain disorders.

BioNTech SE reported financial results for the three months and full year ended December 31, 2021 and provided an update on its corporate progress.

Sterotherapeutics, LLC announced today that it has entered into an exclusive agreement with Moffitt Cancer Center and Florida Atlantic University Research Corporation for a license to novel compounds and methods for the treatment of multiple myeloma.

BD announced the early results and pricing terms of Morgan Stanley & Co. LLC’s previously announced cash tender offers for the notes set forth below, up to a maximum aggregate combined purchase price on such Notes payable in connection with such Offers) of $200,000,000.00.

Receptor Life Sciences Announces FDA Acceptance of IND Application for RLS103 (Inhaled Dry Powder CBD) and Initiation of IND-Opening Clinical Safety and Efficacy Study.

Biome Analytics, the leading cardiovascular performance company, is pleased to introduce the Biome Opportunity Engine™.

Acer Therapeutics Inc. (Nasdaq: ACER), today announced the enrollment of the first patient in its Phase 2a randomized, double-blind, placebo-controlled, dose-ranging trial evaluating the efficacy, safety, and pharmacokinetics (PK) of ACER-801 (osanetant) at different doses, compared to placebo, for the treatment of moderate to severe Vasomotor Symptoms (VMS) associated with menopause.

SciSparc Ltd., a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced the appointment of Professor Avi Schroeder as a member of the Company’s Scientific Advisory Board.

The clinical research business of Thermo Fisher Scientific has won a 2021 TOPRA Award for Regulatory Excellence, recognizing the important role of its regulatory affairs team in expediting vaccine approvals during the COVID-19 global pandemic.

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced that it will report first quarter 2022 financial results on Thursday, April 21, 2022, before the market opens.